Tenaya Therapeutics, Inc. TNYA
Tenaya Therapeutics, Inc. (Nasdaq: TNYA) is a cardio-renal-metabolic drug developer. Its lead program, TN-201, is in Phase 1 for MYBPC3-associated hypertrophic cardiomyopathy (MyPEAK-1). Its next catalyst on record is TN-201: One-year Cohort 2 and two-year Cohort 1 data (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TN-201 — One-year Cohort 2 and two-year Cohort 1 data (Q4 2026). 4 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| TN-201 | MYBPC3-associated hypertrophic cardiomyopathy (Phase 1b/2, enrollment complete) | gene therapy | Phase 1 |
| TN-401 | PKP2-associated arrhythmogenic right ventricular cardiomyopathy (Phase 1b/2, enrollment complete) | gene therapy | Phase 1 |
| TN-301 | HFpEF (HDAC6 inhibitor; Phase 1 healthy-subject study complete) | small molecule | Phase 1 |
Recent results and decisions
- Nov 10, 2025positive MyPEAK-1 (Phase 1b/2a) Cohort 1 showed deepening reductions in biomarkers and LV hypertrophy beyond 52 weeks; robust transduction and MyBP-C expression in Cohort 2; well tolerated at 3E13 and 6E13 vg/kg.
TN-201 achieved robust transduction and durable expression with dose-dependent increase in MyBP-C protein.
Filing - Nov 10, 2025clinical hold MyPEAK-1 is on clinical hold pending a protocol amendment standardizing monitoring and immunosuppression; company does not expect hold to affect milestones.
During this time, MyPEAK-1 is on clinical hold.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 1 cardio-renal-metabolic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.